Published on
CHOP’s Cancer Center helps families manage the extreme emotions elicited by a child’s cancer diagnosis through its world-class, comprehensive, innovative psychosocial services.
Published on
An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.
Published on
CHOP’s clinical and research teams aggressively pursue options in the field of personalized, cellular gene therapies.
Published on
CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.
Published on
The European Commission (EC) approves Kymriah, the first-ever U.S. FDA approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers.
Published on
CHOP has been at the forefront of developing cell therapy to treat ALL. Some next steps include initiating clinical trials for AML and, ultimately, making this treatment work for solid tumors.
Published on
Thanks to a recent initiative at CHOP, patients newly diagnosed with B-cell and T-cell ALL, and lymphoblastic lymphoma, now go home on average 9 days after diagnosis — that's 3 weeks sooner than previous stays.
Published on
Dr. Grupp focuses on required preparations, recovery phase, and potential new applications of CAR T-cell therapy.
Published on
Emily Whitehead, the first pediatric patient to receive CAR T-cell therapy, and her family honor the CHOP team who saved her life with a $250,000 research grant to expand the use of the therapy for relapsed or refractory ALL.
Published on
A new study finds important differences in how cancers develop in children as compared to adults, proving the concept that childhood cancers are not "small adult tumors."